ATRICURE INC misses expectations for EPS and revenue

Trending News 🌧️

Atricure Inc Stock Fair Value – ATRICURE INC ($NASDAQ:ATRC) is a company that manufactures and sells medical devices. The company missed expectations for earnings per share and revenue in its most recent quarter. The company reported earnings per share of $0.06, compared to the $0.07 that was expected by analysts.

ATRICURE INC blamed the miss on lower-than-expected sales in Europe and Asia. The company’s stock price fell on the news.

Earnings

ATRICURE INC reported its earnings for FY2022 Q3 ending September 30. The company earned 315.6M USD in total revenue, and lost 56.0M USD in net income. Compared to the previous year, this represents a 15.1% increase in total revenue, and a 211.6% decrease in net income. ATRICURE INC’s total revenue has grown from 206.5M USD to 315.6M USD over the last three years.

The company attributed the miss to “unfavorable product mix and continued investment in new product development and commercialization.” ATRICURE INC is a medical device company that specializes in minimally invasive cardiac surgery products.

Stock Price

ATRICURE INC missed expectations for EPS and revenue on Thursday, causing their stock to open at $40.2 and close at $41.4, up by 2.5% from the last closing price of $40.4. Media sentiment towards the company is mostly neutral, with some investors disappointed by the earnings miss and others encouraged by the stock’s price increase.

VI Analysis – Atricure Inc Stock Fair Value Calculator

ATRICURE INC is a healthcare company with a strong focus on cardiac and vascular care. The company’s fundamentals reflect its long-term potential, making it an attractive investment proposition. The intrinsic value of ATRICURE INC shares is around $62.9, which suggests that the stock is currently undervalued by 34%.

VI Peers

The company was founded in 2000 and is headquartered in Mason, Ohio. AtriCure’s competitors include Abiomed Inc, LeMaitre Vascular Inc, and Nevro Corp. These companies also provide medical devices and services for the treatment of Afib and other cardiovascular conditions.

– Abiomed Inc ($NASDAQ:ABMD)

Abiomed Inc. is a medical device company that develops and manufactures products to treat congestive heart failure and acute cardiac conditions. The company’s product portfolio includes implantable cardioverter defibrillators, left ventricular assist devices, and heart pumps. Abiomed’s products are used by hospitals and clinics around the world. The company has a market capitalization of $16.86 billion and a return on equity of 10.55%. Abiomed is headquartered in Danvers, Massachusetts.

– LeMaitre Vascular Inc ($NASDAQ:LMAT)

LeMaitre Vascular Inc is a medical device company that specializes in the manufacturing of devices and implants for the treatment of peripheral vascular diseases. The company has a market capitalization of 984.38 million as of 2022 and a return on equity of 6.77%. The company’s products are used by surgeons to treat a variety of vascular conditions, including arterial and venous diseases.

– Nevro Corp ($NYSE:NVRO)

As of 2022, Nevro Corp has a market cap of 1.44B and a Return on Equity of -34.12%. The company is a medical device company that develops and commercializes proprietary neuromodulation solutions for the treatment of chronic pain.

Summary

ATRICURE INC is a medical device company that manufactures and sells devices for the treatment of atrial fibrillation, a heart condition that affects millions of people worldwide. The company has a strong track record of innovation and clinical success, and its products are used by some of the world’s leading cardiac surgeons. Investors considering ATRICURE INC as a potential investment should be aware of the company’s strong track record of innovation and clinical success. Additionally, ATRICURE INC’s products are used by some of the world’s leading cardiac surgeons, which could provide a measure of stability for the company’s future performance.